

## Special Issue

# Evaluation of Emerging Antimicrobials, 2nd Edition

### Message from the Guest Editor

The first edition of the Special Issue “Evaluation of Emerging Antimicrobials” was closed in the first half of 2025, and can be found at the following link: [https://www.mdpi.com/journal/antibiotics/special\\_issues/LR6JHE8B36](https://www.mdpi.com/journal/antibiotics/special_issues/LR6JHE8B36). It focused on antimicrobial agents in the treatment and prevention of infections, and its success has encouraged us to launch a second edition on the same topic. As a continuation of the first Special Issue, we aim to present new chemical agents (NCEs) and their antimicrobial evaluation against different microorganisms. It also encourages any novel advances in the mechanistic insights of known antimicrobial agents toward infections. We welcome research articles and reviews, including discussions of antimicrobial therapy, clinical strategies, and new antimicrobial agent discovery.

---

### Guest Editor

Dr. Dilep Kumar Sigalapalli

Department of Biochemistry, University of Washington, Seattle, WA, USA

---

### Deadline for manuscript submissions

31 August 2026



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/250979](https://www.mdpi.com/si/250979)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://www.mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)